Core Insights - The company reported a full year fiscal 2025 net revenue of $66.4 million and a net loss of $13.6 million [1] - Adjusted EBITDA for fiscal 2025 was $9.2 million, with a cash balance of $31.0 million as of June 30, 2025 [1] - An exclusive agreement was made in June 2025 to commercialize EXXUA™ (gepirone) extended-release tablets, which is expected to be a significant growth catalyst [1] - The anticipated launch of EXXUA in the fourth calendar quarter of 2025 targets the over $22 billion U.S. prescription major depressive disorder market [1] - EXXUA is positioned as a novel first-in-class oral selective serotonin 5HT1a receptor agonist for adults with major depressive disorder [1] - The company will host a conference call and webcast on September 23, 2025, at 4:30 p.m. Eastern time to discuss these results [1]